Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 4233   Home Print this page  Email this page Small font size Default font size Increase font size

  Table of Contents    
Year : 2012  |  Volume : 29  |  Issue : 3  |  Page : 303  

Comments: Other considerations about surgery in lung cancer

1 Department of Lung, Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, I.R. Iran
2 Department of Surgery, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, I.R. Iran

Date of Web Publication28-Jul-2012

Correspondence Address:
Amin Saburi
Department of Lung, Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran
I.R. Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

How to cite this article:
Ghanei M, Saburi A, Akhavan-Moghadam J. Comments: Other considerations about surgery in lung cancer. Lung India 2012;29:303

How to cite this URL:
Ghanei M, Saburi A, Akhavan-Moghadam J. Comments: Other considerations about surgery in lung cancer. Lung India [serial online] 2012 [cited 2020 Jul 11];29:303. Available from: http://www.lungindia.com/text.asp?2012/29/3/303/99133


I read with great interest a recently published article on beneficial aspects of surgery in small cell lung cancer. [1] Prof. Koul skillfully concluded about the therapeutic role of surgery in patients affected by limited-stage of lung cancer (LC) in terms of histopathologic characteristics (small cell or non-cell LC) and staging. Regardless of the discussed subjects, it seems that if a few points are also considered, it will be helpful especially for further studies.

Surgery was usually recommended for limited stage of cancer and a proposed treatment for advanced stages of disease (regardless of the type of pathologic findings) is chemotherapy combined with radiotherapy, although up to about 33% increase in 5-year survival in response to the chemotherapy is expected in patients with limited stage of LC. [2] But there are some newly recognized advantages for surgery even in advanced cancerous lesions. Alpha-N-acetylgalactosaminidase (anagalase) is an important enzyme, which deglycosylates and therefore inactivates human group-specific component (Gc) protein, a well-known vitamin D-binding protein (DBP) or Gc globulin, which has vital role in activation of macrophage to enhance humoral and cellular immune system but some infected cells (e.g., cells infected by HIV) or cancerous cells produce this enzyme and protect themselves against activated macrophages. [3] Hence, total resection or debulkation can reduce amount of this enzyme and can be helpful in every stage theorically. [4]

On the other hand, we have to consider age as a restricting factor in surgery (especially along with additional disabilities), although it has been shown that surgery in older patients with LC can be a beneficial and safe procedure. [5] Recently, minimal invasive surgery was extended in treatment of LC although it has a significant limitation in more internal lesions. [6] There are some recent developments in immune-based chemotherapy but surgery remains as a principle of LC treatment. Further investigations in the role and methods of surgery in patients with higher stage LC are needed because the majority of patients are diagnosed in advanced stages of the LC. [7]

   References Top

1.Koul PA. Surgery in limited-disease small-cell lung cancer. Lung India 2012;29:2-3.   Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Eberhardt W, Korfee S. New approaches for small-cell lung cancer: Local treatments. Cancer Control 2003;10:289-96.   Back to cited text no. 2
3.Nagasawa H, Uto Y, Sasaki H, Okamura N, Murakami A, Kubo S, et al. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res 2005;25:3689-95.   Back to cited text no. 3
4.Yamamoto N, Suyama H, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 2008;122:461-7.   Back to cited text no. 4
5.VanderWalde A, Pal SK, Reckamp KL. Management of non-small-cell lung cancer in the older adult. Maturitas 2011;68:311-21.   Back to cited text no. 5
6.Castillo MD, Heerdt PM. Pulmonary resection in the elderly. Curr Opin Anaesthesiol 2007;20:4-9.   Back to cited text no. 6
7.Rawat J, Sindhwani G, Gaur D, Dua R, Saini S. Clinico-pathological profile of lung cancer in Uttarakhand. Lung India 2009;26:74-6.  Back to cited text no. 7
[PUBMED]  Medknow Journal  

This article has been cited by
1 Authors′reply
Prabhu Ramnath, V.G., Narasimhan, R.
Lung India. 2012; 29(3): 303-304


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded241    
    Comments [Add]    
    Cited by others 1    

Recommend this journal